NCT02180867 · OUTCOME

Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery · Source last updated 2026-06-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of patients
Interval / dispersion: 95% Confidence Interval
Time frame: Week 10 after induction

What was measured

A responder is defined by more than 90% tumor necrosis at week 10. A non-responder has less than 90% necrosis or progressive disease before week 10.

Analysis population: It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose Level 0 RT. 3 Regimen C patients excluded: 1 patient did not receive treatment and 2 missing review; 4 Regimen D patients excluded due to missing review.

Groups in this outcome

Dose-Finding Level 1 RT

Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2

Dose-Finding Level 2 RT

Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2

Regimen C

Regimen C: Radiation therapy plus pazopanib

Regimen D

Regimen D: Radiation therapy alone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Dose-Finding Level 1 RT	3
Dose-Finding Level 2 RT	5
Regimen C	3
Regimen D	2

Reported measurements

Source class 1

Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Upper	Comment
Dose-Finding Level 1 RT	0	Not reported	0	Not reported
Dose-Finding Level 2 RT	40	Not reported	82.94	Not reported
Regimen C	0	Not reported	0	Not reported
Regimen D	0	Not reported	0	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0
upper Limit
0
value
0
group Id
OG001
lower Limit
0
upper Limit
82.94
value
40
group Id
OG002
lower Limit
0
upper Limit
0
value
0
group Id
OG003
lower Limit
0
upper Limit
0
value
0

denoms

counts
group Id
OG000
value
3
group Id
OG001
value
5
group Id
OG002
value
3
group Id
OG003
value
2
units
Participants

description

A responder is defined by more than 90% tumor necrosis at week 10. A non-responder has less than 90% necrosis or progressive disease before week 10.

dispersion Type

95% Confidence Interval

groups

description
Dose-Finding Level 1 RT: Adult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2
id
OG000
title
Dose-Finding Level 1 RT
description
Dose-Finding Level 2 RT: Adult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2
id
OG001
title
Dose-Finding Level 2 RT
description
Regimen C: Radiation therapy plus pazopanib
id
OG002
title
Regimen C
description
Regimen D: Radiation therapy alone
id
OG003
title
Regimen D

param Type

NUMBER

population Description

It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose Level 0 RT. 3 Regimen C patients excluded: 1 patient did not receive treatment and 2 missing review; 4 Regimen D patients excluded due to missing review.

reporting Status

POSTED

time Frame

Week 10 after induction

title

Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10

type

PRIMARY

unit Of Measure

Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice